POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biologics AB Initio, Based on the Results of the Apraisal Multicenter Observational Study in Greece

Elena Sotiriou ,Z Anagnostopoulos,Kd Tomai,A Kekki,Konstantina Mavridou ,Alexandros A Drosos ,Efterpi Zafiriou ,Natalia Rompoti ,Evangelia Rovithi ,Konstantinos Krasagakis ,Vasiliki Chasapi ,O Neofotistou ,I Lefaki ,Christina Kalinou ,Nikolaos Antonakopoulos ,P Aronis ,Efthymia Gialeli ,John Katsantonis ,E Pokas ,A Protopapa ,Elizabeth Lazaridou ,Evangelia Papadavid ,Marina Papageorgiou ,Markos Papakonstantis

doi:10.1016/j.jval.2021.11.336

POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biologics AB Initio, Based on the Results of the Apraisal Multicenter Observational Study in Greece

Elena Sotiriou , Z Anagnostopoulos + Show 22 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.336

Copy DOI

Journal: Value in Health	Publication Date: Jan 1, 2022
License type: elsevier-specific: oa user license

Affiliation: Aristotle University of Thessaloniki, University of Ioannina, General Hospital of Attica, University Hospital of Larissa, National and Kapodistrian University of Athens, The General Hospital of Heraklion "Venizeleio-Pananio", University Hospital of Heraklion, Andreas Sygros Hospital, Agia Olga Hospital, Euromedica, Agios Pavlos General Hospital, Hellenic Airforce General Hospital, General University Hospital of Patras, Tzaneion General Hospital, Hospital Venereal and Skin Diseases Thessaloniki, 401 General Military Hospital of Athens

#Cost-per-responder #Psoriasis Area Severity Index + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The 52-week treatment cost per patient achieving ≥75% reduction in Psoriasis Area Severity Index [PASI75 cost-per-responder (CPR)] and per patient attaining Dermatology Life Quality Index (DLQI) 0/1 (DLQI-0/1 CPR) was estimated in patients initiated and remaining on apremilast (APR) or switching to biologics, and patients hypothetically treated with biologics ab initio.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Value in Health

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.